#United States #San Mateo, California #Vivace Therapeutics #VT3989 #ESMO

New Clinical Data Release by Vivace Therapeutics

Vivace Therapeutics, a pioneering company involved in the research and development of small molecule cancer therapies, is set to present significant data regarding its novel treatment targeting the Hippo pathway at the upcoming European Society for Medical Oncology (ESMO) Congress scheduled for October 17-21, 2025, in Berlin, Germany. The presentation will focus on VT3989, a first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor that showcases considerable therapeutic potential, particularly for treating mesothelioma.

Focus of the Presentation

The oral presentation will be delivered by Dr. Timothy A. Yap, the Head of Clinical Development in the Therapeutics Discovery Division at the renowned University of Texas, M.D. Anderson Cancer Center. Attendees can look forward to comprehensive insights into the safety and efficacy of VT3989 through data collected from a Phase 1/2 clinical trial.

The specifics of the presentation are as follows:

• - Title: Safety and efficacy of first-in-class, YAP/TEAD inhibitor, VT3989 in refractory pleural and non-pleural mesothelioma: A Phase I/II study.
• - Presenting Author: Dr. Timothy A. Yap, M.D., Ph.D.
• - Session: Proffered Paper Session – Mesothelioma and thymic tumors targeting and breaking through.
• - Date/Time: Sunday, October 19, 2025, from 4:30 PM to 6:00 PM CEST, with the specific presentation from 4:40 PM to 4:50 PM CEST.
• - Location: Hanover Auditorium - Hall 7.2c.

Results of the Clinical Trial

Earlier results from the ongoing Phase 1/2 trial have shown that VT3989 is generally well-tolerated, demonstrating durable antitumor responses among patients suffering from advanced malignant mesothelioma, alongside tumors containing neurofibromatosis type 2 (NF2) mutations. This crucial study is designed as a multi-center, open-label trial and aims to evaluate the safety, tolerability, pharmacokinetics (PK), and biological activity of VT3989 specifically aimed at patients harboring refractory metastatic solid tumors, including both pleural and non-pleural malignant mesothelioma.

Notably, the study features a dual-phase layout, comprising dose escalation and dose expansion phases, to rigorously assess the drug's impact and effectiveness.

About Vivace Therapeutics

Headquartered in the San Francisco Bay Area, Vivace Therapeutics is dedicated to developing first-in-class cancer therapies that specifically target the Hippo pathway due to its relevance in oncology and potential in addressing significant unmet medical needs. The company has successfully raised approximately $105 million, fueling its commitment to innovating treatments aimed at severe forms of carcinomas. Through rigorous clinical research and development, Vivace continues to push the boundaries of cancer therapy.

For additional details and updates on their groundbreaking activities, please visit Vivace Therapeutics.

Conclusion

As Vivace Therapeutics gears up to unveil these transformative findings at ESMO 2025, the global medical community remains keenly interested in how VT3989 could revolutionize treatment options for patients battling difficult-to-treat cancers like mesothelioma. The confluence of cutting-edge science and clinical innovation continues to chart new paths in the fight against cancer, underscoring the significance of ongoing research and collaboration in the healthcare industry.